Andy Tan

Andy leads the Immune Cell Manufacturing group at BTI, A*STAR which focuses on developing processes and media optimization to support the lab- and bioreactor-scale production of unmodified or chimeric antigen receptor (CAR)-engineered T and NK cells for tumor immunotherapy. He was the lead investigator in a joint laboratory with a local contract development and manufacturing organization (CDMO) to establish large scale expansion of CAR virus-producing cells and CAR-T cells. Andy also co-directs the Centre of Innovation for Sustainable Banking and Production of Cultivated Meats (CRISP Meats) which develops innovative technologies to enable manufacturing of cultivated meat. His group also optimizes nucleic acid- and immune-based analytics for biologics characterization. Andy received his BSc and MSc in Physics from National University of Singapore (NUS) and PhD in Immunology from NUS Graduate School for Integrative Sciences and Engineering. He then completed postdoctoral training in Immunogenomics at John Curtin School of Medical Research, Australian National University before joining BTI.